Clinical Trials

1 trials
RecentStart dateEnrollment
Graft vs Host Disease × sargramostim × Dermatologic × Clear all
NCT00053157 2022-10-05

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Roswell Park Cancer Institute

Phase NA Completed
10 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmSarcoma

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Burkitt Lymphoma, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Dendritic Cell Sarcoma, Interdigitating, Primary Myelofibrosis